|February 4, 2013|
|16:06 EDT||EW||Edwards Lifesciences sees FY13 adjusted EPS $3.21-$3.31, consensus $3.27|
Sees FY13 revenue $2.1B-$2.2B consensus $2.14B.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
|May 15, 2013|
|07:17 EDT||EW||Edwards Lifesciences share repurchases positive, says Wells Fargo|
Subscribe for More Information
|May 14, 2013|
|09:27 EDT||EW||Edwards Lifesciences CEO to purchase $5M of company stock|
The company announced that Michael A. Mussallem, Edwards' chairman and CEO, will make a $5M cash purchase of newly issued shares of Edwards common stock.
|09:26 EDT||EW||Edwards Lifesciences announces new $750M share repurchase program|
Edwards Lifesciences announced that its board has authorized a new share repurchase program to acquire up to an additional $750M of the company's outstanding common shares. As of March 31, Edwards had approximately $140M remaining of its current $500M share repurchase program, which was authorized in September 2011. Edwards expects to utilize the remainder of the $500M repurchase authorization during Q2.
|09:22 EDT||EW||Edwards Lifesciences CFO announces retirement|
Edwards Lifesciences announced that Thomas M. Abate, the company's CFO, plans to retire later this year. Abate plans to remain CFO until his successor is in place. The company has retained Peter Crist of Crist/Kolder Associates to assist in the CFO search.